α-Synuclein Aggregation in Treatment of Parkinson's Disease

Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.

Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease

Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies

Curcumin Interacts with α-Synuclein Condensates To Inhibit Amyloid Aggregation under Phase Separation

Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway

Mechanism of Anti-α-Synuclein Immunotherapy

Cells, Free Full-Text

α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis - ScienceDirect

Liquid-liquid Phase Separation of α-Synuclein: A New Mechanistic Insight for α-Synuclein Aggregation Associated with Parkinson's Disease Pathogenesis - ScienceDirect

α-synuclein strains that cause distinct pathologies differentially inhibit proteasome

Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration, Acta Neuropathologica Communications

Intermediates of α-synuclein aggregation: Implications in Parkinson's disease pathogenesis - ScienceDirect

A Peptide Approach to Reducing alpha-Synuclein in Parkinson's Disease

PAP reduced α-synuclein expression and aggregation in MPTP/P-treated

Heparan sulfate proteoglycans mediate prion-like α-synuclein toxicity in Parkinson's in vivo models

Initiation and progression of α-synuclein pathology in Parkinson's disease